title: Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study.
abstract: Adductor spasticity in children with cerebral palsy (CP) impairs motor function and development. In a placebo-controlled, double-blind, randomized multicentre study, we evaluated the effects of botulinum toxin A(BTX-A) in 61 children (37 males, 24 females; mean age 6 years 1 month [SD 3y 1mo]) with CP (leg-dominated tetraparesis, n=39; tetraparesis, n=22; GMFCS level I, n=3; II, n=6; III, n=17; IV, n=29; V, n=6). Four weeks after treatment, a significant superiority of BTX-A was observed in the primary outcome measure (knee-knee distance 'fast catch', p=0.002), the Ashworth scale (p=0.001), and the Goal Attainment Scale (p=0.037).
authors.affiliation: Children's University Hospital, Freiburg University, Germany. mall@kikli.ukl.uni-freiburg.de
authors.forename: Volker
authors.initials: V
authors.lastname: Mall
authors.forename: Florian
authors.initials: F
authors.lastname: Heinen
authors.forename: Andrea
authors.initials: A
authors.lastname: Siebel
authors.forename: Christoph
authors.initials: C
authors.lastname: Bertram
authors.forename: Ulrich
authors.initials: U
authors.lastname: Hafkemeyer
authors.forename: Jörg
authors.initials: J
authors.lastname: Wissel
authors.forename: Steffen
authors.initials: S
authors.lastname: Berweck
authors.forename: Fritz
authors.initials: F
authors.lastname: Haverkamp
authors.forename: Günter
authors.initials: G
authors.lastname: Nass
authors.forename: Leo
authors.initials: L
authors.lastname: Döderlein
authors.forename: Nico
authors.initials: N
authors.lastname: Breitbach-Faller
authors.forename: Wilhelm
authors.initials: W
authors.lastname: Schulte-Mattler
authors.forename: Rudolf
authors.initials: R
authors.lastname: Korinthenberg
mesh_terms: D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D002547:Cerebral Palsy / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006621:Hip Joint / Q000502:physiology; D006801:Humans; D007719:Knee Joint / Q000502:physiology; D008297:Male; D009128:Muscle Spasticity / Q000188:drug therapy; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010919:Placebos; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D010919:Placebos; D019274:Botulinum Toxins, Type A